4.5 Article

Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Platform to Study SARS-CoV-2 Related Myocardial Injury

Journal

CIRCULATION JOURNAL
Volume 84, Issue 11, Pages 2027-2031

Publisher

JAPANESE CIRCULATION SOC
DOI: 10.1253/circj.CJ-20-0881

Keywords

COVID-19; Myocarditis; SARS-CoV-2; Stem cells

Funding

  1. Theme-based Research Scheme, University Grant Committee [T11-707/15-R]
  2. University Development Fund, The University of Hong Kong, Hong Kong SAR, China
  3. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Ministry of Education, China

Ask authors/readers for more resources

Background: SARS-CoV-2 infection is associated with myocardial injury, but there is a paucity of experimental platforms for the condition. Methods and Results: Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) infected by SARS-CoV-2 for 3 days ceased beating and exhibited cytopathogenic changes with reduced viability. Active viral replication was evidenced by an increase in supernatant SARS-CoV-2 and the presence of SARS-CoV-2 nucleocaspid protein within hiPSC-CMs. Expressions of BNP, CXCL1, CXCL2, IL-6, IL-8 and TNF-alpha were upregulated, while ACE2 was downregulated. Conclusions: Our hiPSC-CM-based in-vitro SARS-CoV-2 myocarditis model recapitulated the cytopathogenic effects and cytokine/chemokine response. It could be exploited as a drug screening platform.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available